TSLP/IL-33 bispecific antagonist antibody (Odyssey Therapeutics)

N/A

Report date: 2025/03/13 16:56:00

Base Information

Drug NameTSLP/IL-33 bispecific antagonist antibody (Odyssey Therapeutics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionInterleukin-33 inhibitorsThymic stromal lymphopoietin inhibitors

TargetsInterleukin-33Thymic stromal lymphopoietin

Therapy Area/IndicationsAsthma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOdyssey Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesOdyssey Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsAsthma

Inactive IndicationsN/A

Other Information

ATC CodeN/A